NCT02282826: A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis |
|
|
| Completed | 1 | 48 | Europe | GZ402668, placebo, acyclovir | Genzyme, a Sanofi Company | Progressive Multiple Sclerosis | 03/16 | 03/16 | | |
NCT02977533: A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis |
|
|
| Completed | 1 | 20 | Europe | GZ402668, Placebo, Acyclovir | Sanofi | Progressive Multiple Sclerosis | 05/18 | 05/18 | | |
